503A Category 1, 2, and 3 bulk substances: what the lists mean

01

Start with the difference between a nomination category and the final list

Section 503A describes conditions under which a qualifying state-licensed pharmacy, federal facility, or licensed physician may compound a drug for an identified individual patient. FDA explains that a bulk drug substance generally must meet one of three threshold routes: comply with an applicable USP or National Formulary monograph, be a component of an FDA-approved drug when no applicable monograph exists, or appear on the final 503A Bulks List when neither of the first two routes applies. Other statutory and state-law conditions still matter.

Categories 1, 2, and 3 are different. FDA created them for an interim policy covering substances nominated for possible future inclusion while the agency works through evaluations and rulemaking. A category entry is therefore a status in a nomination process, not an approved-drug record, a completed rule, or a determination that every compounded preparation using the substance qualifies for section 503A exemptions.

This distinction is easy to lose in clinic or pharmacy marketing. Phrases such as nominated, under review, Category 1, discussed by an advisory committee, proposed for inclusion, and on the final list describe different stages. The exact stage and date should appear next to any claim.

• →Final 503A Bulks List: a regulation-based list of named bulk substances.
• →Category 1, 2, or 3: an interim-policy classification for certain nominations.
• →FDA-approved drug: a specific product with an approved application and labeling.
• →Compounded drug: not FDA-approved and not reviewed before marketing for safety, effectiveness, and quality.

02

What Category 1 means—and what it does not

FDA describes Category 1 as substances that may be eligible for the 503A Bulks List, were nominated with sufficient supporting information for evaluation, and do not appear on another identified list. The agency’s interim guidance describes circumstances in which it does not intend to take action against a qualifying compounder solely for using a Category 1 substance before FDA completes the list decision.

That policy is conditional. It does not erase the patient-specific prescription requirement, applicable state law, ingredient-quality requirements, labeling obligations, restrictions on essentially copying commercial products, or the other conditions of section 503A. A seller cannot establish compliance by pointing only to a Category 1 spreadsheet.

Enforcement discretion also is not approval. It expresses how an agency intends to prioritize enforcement under stated circumstances; it does not find a compounded product safe or effective, authorize a marketed indication, or guarantee that a pharmacy followed the conditions. The policy can change as FDA evaluates a substance or identifies new risk information.

03

What Category 2 means for peptide research

FDA places a nominated substance in Category 2 when the nomination included enough information for evaluation but the agency identified significant safety risks relating to its use in compounding. FDA says it does not extend the Category 1 interim policy to these substances and would consider enforcement under its general policies.

The agency maintains a public safety-risk page that names multiple peptide-related substances. Depending on the substance and route, FDA discusses limited or absent human exposure data, potential immunogenicity, aggregation, peptide-related impurities, difficulty characterizing the active ingredient, and reported serious adverse events. The wording is substance-specific; one entry should not be copied onto a different peptide or route.

Category 2 does not mean that FDA proved every marketed vial caused harm. It means the agency identified a regulatory safety concern sufficient to withhold the Category 1 policy while evaluation continues. Consumers should preserve that uncertainty without weakening the warning or converting it into an unsupported claim about a specific patient or lot.

• →Match the exact substance and form, including free base, salt, or acetate.
• →Read whether FDA’s concern is route-specific.
• →Separate absence of evidence from evidence of no risk.
• →Do not treat a later committee discussion as immediate removal from Category 2.

04

What Category 3 means after the January 2025 policy update

Category 3 historically covered substances that might be eligible for the final list but were nominated without enough supporting information for FDA to evaluate them. FDA states that they are not within the Category 1 interim policy and that the agency would consider enforcement under its general policies. A substance could be re-nominated with sufficient information.

Insufficient information is not a favorable safety finding. It means FDA could not complete the intended evaluation from the nomination record. Marketing that translates Category 3 into low risk, temporarily approved, grandfathered, or permitted pending paperwork is not supported by FDA’s description.

The January 2025 final guidance changed how new nominations are handled. FDA says it does not intend to place substances nominated on or after January 7, 2025 into the three interim categories. Older Category 1 entries can remain within the described policy until FDA decides the list question or removes the substance, including because of safety information. The date of the nomination and the current version of FDA’s page therefore matter.

05

How to verify a provider or pharmacy claim about the categories

Ask for the exact legal name of the dispensing pharmacy, the physical compounding location, the ingredient name and form, route, strength, intended use, and the federal pathway being claimed. Then open FDA’s current 503A bulk-substance page and its linked files. A screenshot without a URL, category heading, and access date is not enough because entries and policies can change.

Next, check whether the seller has confused the 503A nomination categories with the separate 503B framework for outsourcing facilities. A pharmacy’s state license, an outsourcing facility’s FDA registration, a bulk-substance category, and a product’s approval status answer different questions. Verify each through its own source.

Finally, ask what patient-specific clinical difference or compounding need is documented and who made that determination. The answer does not prove compliance, but it helps distinguish a patient-specific prescription pathway from mass marketing. Treatment decisions and individual risk questions belong with an appropriately licensed clinician and the dispensing pharmacist.

• →Request a direct FDA link and the date checked.
• →Confirm whether the claim concerns 503A or 503B.
• →Match the exact ingredient form and route.
• →Verify the prescriber and pharmacy separately.
• →Treat “Category 1 approved” or “FDA-approved bulk peptide” as inaccurate wording.

06

Red flags and limits of category research

Pause when a marketer displays Category 1 as an approval badge, describes Category 2 as a temporary paperwork issue, or says Category 3 proves a substance is safe because FDA found no problem. Other warning signs include omitting the exact pharmacy, using one substance’s status for a blend, and treating an advisory vote or nomination as a final rule.

Public lists also have limits. They do not show whether an individual prescription was valid, whether a pharmacy complied with all federal and state requirements, whether the exact lot met specifications, or whether a product is appropriate for a patient. FDA’s interim policy is written for compounders and enforcement decisions, not as a consumer treatment recommendation.

Use the category as one dated fact in a larger verification record. Preserve the source, the exact wording, and any unresolved mismatch. If a clinic cannot explain the product’s identity and pathway without turning a regulatory category into a promise of quality or effectiveness, do not rely on the claim.